

# Curriculum Vitae

## Personal information

First name(s) / Surname(s) **Alessandro Tuzi**  
Address Viale Borri 57 (ASST dei Sette Laghi), 21100 Varese  
Tel +390332278558 +390332393047  
E-mail(s) [alessandro.tuzi@asst-settelaghi.it](mailto:alessandro.tuzi@asst-settelaghi.it)  
Nationality Italian  
Date of birth  
Gender

## Desired employment / Occupational field **Medical Oncology**

### Work experience

Dates	01/02/2013 - ongoing
Occupation or position held	Oncologist
Main activities and responsibilities	All solids tumors, myeloma, lymphoma, palliative care, simultaneous home care.
Name and address of employer	ASST dei Sette Laghi (Varese, Verbano) – Oncologia. Viale Borri 57, 21100 Varese
Dates	16/05/2012 – 31/01/2013
Occupation or position held	Oncologist Researcher
Main activities and responsibilities	Gastrointestinal cancer - Sarcoma - Breast cancer - Gynecologic cancer - Rare tumors
Name and address of employer	Oncologia Medica B – C, Centro di Riferimento Oncologico (CRO) 2 V. Franco Gallini, 33081 AVIANO (Italy) Human health and social work activities
Dates	28/04/2011 – 28/03/2012
Occupation or position held	Medical assistant
Main activities and responsibilities	Breast cancer - Gynecologic cancer - Gastrointestinal cancer - Sarcoma - Rare tumors
Name and address of employer	Oncologia Medica B – C, Centro di Riferimento Oncologico (CRO) 2 V. Franco Gallini, 33081 AVIANO (Italy) Human health and social work activities
Type of business or sector	Human health and social work activities
Dates	15/03/2008 - 27/04/2011
Occupation or position held	Medical assistant
Main activities and responsibilities	All solid tumors (especially gastrointestinal, genito-urinary and lung cancer)
Name and address of employer	Policlinico Umberto I - "Sapienza" Università di Roma 324 V. Regina Elena, 00161 Roma (Italy) Human health and social work activities
Type of business or sector	Human health and social work activities
Dates	01/12/2007 - 28/02/2008
Occupation or position held	Medical visitor

Main activities and responsibilities	All solid tumors																																								
Name and address of employer	UOC Oncologia B - Policlinico Umberto I - "Sapienza" Università di Roma 324 V. Regina Elena, 00161 Roma (Italy)																																								
Type of business or sector	Human health and social work activities																																								
Dates	01/09/2008 - 25/04/2011																																								
Occupation or position held	Medical visitor																																								
Main activities and responsibilities	All solid tumors																																								
Name and address of employer	Clinic "Nostra Signora della Mercede" Via Tagliamento, Roma (Italy)																																								
Dates	01/09/2008 - 25/04/2011																																								
Occupation or position held	Teacher																																								
Main activities and responsibilities	Oncology and Pathology Lectures																																								
Name and address of employer	"Corso di Laurea Infermieristica - ASL RM E" Ospedale S. Spirito - "Sapienza" Università di Roma 1 Lungotevere in Sassia, 00193 Roma (Italy)																																								
<b>Education and training</b>																																									
Dates	26/10/2007 and 29/03/2012																																								
Title of qualification awarded	Medical Doctor and Medical Oncologist <ul style="list-style-type: none"> <li>Graduation in Medicine and Surgery with grades <i>110/110 and honours</i>, by the "Sapienza" University of Rome, Italy, discussing the experimental thesis: "The chemokine CXCL8 in colorectal cancer neoangiogenesis: role of resistance to anti-VEGF therapy"</li> <li>Specialization in Medical Oncology with grades <i>70/70 and honours</i>, by the "Sapienza" University of Rome, Italy, discussing the experimental thesis: "Late Tamoxifen in women with breast cancer"</li> </ul>																																								
Principal subjects / occupational skills covered	All solid tumors. Mieloma. Lymphoma. Palliative Care (also home care).																																								
Name and type of organisation providing education and training	"Sapienza" Università di Roma 1 Piazzale Aldo Moro, 00161 Roma (Italy)																																								
<b>Personal skills and competences</b>																																									
Mother tongue(s)	<b>Italian</b>																																								
Other language(s)																																									
Self-assessment <i>European level</i> (*)																																									
<b>French</b>																																									
<b>English</b>																																									
	<table border="1"> <thead> <tr> <th colspan="4">Understanding</th> <th colspan="4">Speaking</th> <th colspan="2">Writing</th> </tr> <tr> <th colspan="2">Listening</th> <th colspan="2">Reading</th> <th colspan="2">Spoken interaction</th> <th colspan="2">Spoken production</th> <th colspan="2"></th> </tr> </thead> <tbody> <tr> <td>B2</td> <td>Independent user</td> <td>C1</td> <td>Proficient user</td> <td>B2</td> <td>Independent user</td> <td>B2</td> <td>Independent user</td> <td>B2</td> <td>Independent user</td> </tr> <tr> <td>B1</td> <td>Independent user</td> <td>C1</td> <td>Proficient user</td> <td>A2</td> <td>Basic User</td> <td>A2</td> <td>Basic User</td> <td>B1</td> <td>Independent user</td> </tr> </tbody> </table>	Understanding				Speaking				Writing		Listening		Reading		Spoken interaction		Spoken production				B2	Independent user	C1	Proficient user	B2	Independent user	B2	Independent user	B2	Independent user	B1	Independent user	C1	Proficient user	A2	Basic User	A2	Basic User	B1	Independent user
Understanding				Speaking				Writing																																	
Listening		Reading		Spoken interaction		Spoken production																																			
B2	Independent user	C1	Proficient user	B2	Independent user	B2	Independent user	B2	Independent user																																
B1	Independent user	C1	Proficient user	A2	Basic User	A2	Basic User	B1	Independent user																																
	(*) <a href="#">Common European Framework of Reference (CEF) level</a>																																								
Social skills and competences	- Good communication skills - Good ability to adapt to multicultural environments - Team spirit																																								
Organisational skills and competences	- Sense of organisation - Part of the multidisciplinary team (experience in Liver Tumor Board - Colorectal Cancer Group - Breast																																								

Unit – Sarcoma Unit – Thoracic Unit)

Computer skills and competences

- Good command of Microsoft Office™ tools (Word™, Excel™ and PowerPoint™);
- Good command of PubMed
- Good command of "G2" (Friuli Venezia Giulia) - "Onconet" (Lazio) – Ticket, JBook and Portale di Reparto/Monitor (Lombardia) programs for creating database of cancer patients and treatment options

**Additional information**

***Research activities as co-investigator in various clinical trials and all of these were follow according to GCP:***

- A phase III randomized trial of Folfxiri + Bevacizumab vs Folfiri + Bevacizumab as first-line treatment for metastatic colorectal cancer.

Protocol Code: 2008-001537-10

Sponsor: G.O.N.O. Gruppo Oncologico del Nord Ovest

- Optimization of Erlotinib for the treatments of patients with advanced non small cell lung cancer: an Italian randomized trial.

Protocol Code: 2007-004786-17

Sponsor: A.O. Fatebenefratelli e Oftalmico – Milano

- Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer

Protocol Code: CA180-227.

Sponsor: BRISTOL-MYERS SQUIBB S.r.l.

- A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Protocol Code: CA163-115

Sponsor: BRISTOL-MYERS SQUIBB S.r.l.

- Pan European Advanced Breast CancEr Cohort Study (PEACE Study): Therapeutic Pattern of Care in Advanced Breast Cancer Patients

Protocol Code: CA163-123

Sponsor: BRISTOL-MYERS SQUIBB S.r.l.

- Eribulina sarcomi/Eisai: Studio di fase III, multicentrico, in aperto, randomizzato, per confrontare l'efficacia e la sicurezza di Eribulina verso Dacarbazina in soggetti affetti da sarcoma dei tessuti molli".

Prot E7389-G000-309, EUDRACT 2010-024483-17

Promotore Eisai Limited, Hatfield, UK; Centro Coordinatore per l'Italia INT, Milano, Dr. Paolo Casali

- Mek-003/Merk: Studio randomizzato di fase II con l'inibitore della MEK MSC1936369B o con placebo in associazione a gemcitabina nei soggetti con carcinoma del pancreas metastatico.

EudraCT 2009-011992-61

Promotore Merck Serono sS.A.- Ginevra, Centro Coordinatore per l'Italia IRCCS Istituto Regina Elena (IFO) Roma Dr Michele Milella

- DOC2: Studio di fase II della combinazione di docetaxel, oxaliplatino e capecitabina (DOC) in pazienti affetti da carcinoma gastrico non pre-trattati. Studio DOC2

Protocol code N°: CRO-2011-12 Codice EudraCT: 2011-001720-37

- IOPS Study: Italian Oncologic Pain multiSetting Multicentric Survey (IOPSMS).

- MANILA Trial: Maintenance metronomic per os navelbine in advanced NSCLC patients after

previous platinum based chemotherapy: a multicenter randomized best supportive care controlled phase II study MA.NI.LA. Trial

- STOP Trial: Identificazione di polimorfismi predittivi la tossicità correlata al trattamento con bevacizumab: SToP trial.

- SINTART-1 Trial: Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, surgery, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in operable patients.

Protocol Code: SINTART1

EudraCT Number: 2013-000075-33

- SINTART-2 Trial: Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in inoperable patients.

Protocol Code: SINTART2

EudraCT Number: 2013-000580-93

- ICOS-ONE Study: Prevention of anthracyclina induced cardiotoxicity.

**Abstracts:**

- Single centre clinical experience with Fulvestrant in pretreated postmenopausal patients with metastatic breast cancer. Fabbri M.A, Ciprotti M., Trani L., Puglisi M., Pezzoli V., Passaro A., **Tuzi A.**, Ferraldeschi R., D'Auria G., Barni S., Naso G. *Annals of Oncology*; 2008 Oct. Vol. 19 Supplement 9: ix98. Abstract L48.

*Selected for Poster Presentation AIOM 2008*

- Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy. Rocchi A., **Tuzi A.**, Passaro A., Altavilla A., Truscelli K., Naso G., Cortesi E. *Annals of Oncology*; 2008 Oct. Vol. 19 Supplement 9: ix20. Abstract B42.

- Trichomegaly of the eyelash induced by Erlotinib therapy. R. Iacovelli, A. Palazzo, P. Trenta, B. Cimadon, **A. Tuzi**, A. Pellegrino, E. Cortesi, G. Naso. *Lung Cancer*; 2009. Vol. 64, Supp 1;S59.

*Selected for Poster Discussion EMCTO 2009*

- Bevacizumab (BEV) in combination with FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5-FU/LV) in metastatic colorectal cancer (mCRC): updated results of a phase II G.O.N.O. trial. G. Masi, L. Salvatore, L. Fornaro, E. Vasile, G.G. Baldi, I. Stasi, A. Ciarlo, **A. Tuzi**, M. Andreuccetti, A. Falcone. *European Journal of Cancer*; 2009. Supplement Vol. 7 n. 2 Abstract 6081

- Titration with normal-release oral morphine in patients with moderate to severe cancer pain. M. Mazzoli, M. Puglisi, A. Passaro, A. Altavilla, K. Truscelli, ML Mancini, P. Trenta, **A. Tuzi**, D. Conte, A. Pellegrino, A. Palazzo, R. Iacovelli, M.A. Fabbri, E. Cortesi. *Annals of Oncology*; 2009 Oct. Vol. 20, Supplement 8: viii8. Abstract B82.

- Breast cancer resistance to anthracyclines and taxanes under a magnifying lens: emerging role of

circulating tumor cells. A. Petracca, C. Nicolazzo, A. Palazzo, **A. Tuzi**, A. Passaro, A. Altavilla, E. Cortesi, G. Naso, C. Raimondi, P. Gazzaniga. *Annals of Oncology*; 2010 May. Vol. 21 Supplement 4: iv49-59. Abstract 106.

- Drug resistance profile of circulating tumor cells in metastatic colon cancer: predictive significance. Nicolazzo C, Petracca A, Raimondi C, **Tuzi A**, Palazzo A, Altavilla A, Truscelli K, Mancini ML, Cortesi E, Gazzaniga P. *Annals of Oncology*; 2010 July. Vol. 21 Supplement 6: vi32. Abstract 0006.

*Selected for Poster Presentation World GI Congress, Barcelona 2010 – Presented by Tuzi A.*

- Analysis of elderly population treated with Erlotinib for non-small cell lung cancer (NSCLC). Iacovelli R., Palazzo A., Pochesci A., Palleschi M., Campenni G., Risi E., Pellegrino A., **Tuzi A.**, Raimondi C., Mezi S., Cortesi E. *Tumori*; 2010 October. Vol. 10 Abstract D28.

- Bevacizumab (BV) in combination with FOLFOXIRI compared to BV plus FOLFIRI as first line treatment of metastatic colorectal cancer (MCRC): preliminary safety results of the TRIBE study by the GRUPPO ONCOLOGICO NORD-OVEST (GONO). Masi G., Loupakis F., Frustaci S., **Tuzi A.**, Tomasello, G., Ricasoli M., Banzi M., Ricci V., Sonaglio C., Racca P., Zaniboni A., Cupini S., Vitello S., Tonini G., Dargenio F., Allegrini G., Andreuccetti M., Boni L., Falcone A. *Tumori*; 2010 October. Vol. 10 Abstract A8.

- Safety of adjuvant trastuzumab (T) in elderly patients with breast cancer. P. Carli, L. Militello, S. Leo, A. Brunello, S. Spazzapan, C. Lestuzzi, **A. Tuzi**, S. Scalone, A. V. Lorusso, Veronesi and D. Crivellari.

*Selected for Poster Presentation SIOG 2011*

- E. Bolzacchini, **A. Tuzi**, I. Vallini, G. Pinotti; Survey on prevalence and management of breakthrough cancer pain: a single center experience. *Ann Oncol* 2016; 27 (suppl\_4).
- E. Bolzacchini, F. Dentali, T. Tartaro, **A. Tuzi**, I. Proserpio, G. Pinotti; New biomarkers of sunitinib efficacy in metastatic renal cell carcinoma. *Ann Oncol* 2015; 26 (suppl\_6).

### **Publications:**

- La terapia a bersaglio molecolare nel trattamento del tumore del polmone non a piccole cellule: stato dell'arte e prospettive future. Pochesci M, Trenta P, **Tuzi A**, De Benedetto A. *Giornale di Oncologia Geriatrica*, N. 1/2 2010

- Carcinoma della prostata: il trattamento ormonale nella malattia avanzata. D. Modica, **A. Tuzi**, E. Cortesi *Giornale di Oncologia Geriatrica*, N. 1 2011

- Extraperitoneal rectal cancer: chemo-radiotherapy treatments. Cortesi E, **Tuzi A**, Musio D. *Ann Ital Chir.* 2010 Jul-Aug;81(4):247-54

- Umbilical node as first clinical appearance in a patient with a high tumor burden. Iacovelli R, Trenta P, **Tuzi A**, Palazzo A, Cortesi E. *Am Surg.* 2011 Nov;77(11):E248-9.

- Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, **Tuzi A**, Granetto C, Brunetti IM, Ricci S, Falcone A. *Clin Colorectal Cancer.* 2012 Mar;11(1):71-6. Epub 2011 Sep 8

- Medical treatment of advanced or metastatic gastric cancer. **Alessandro Tuzi**, Angela

Buonadonna, Gian Maria Miolo, Elena Torrisi, Sergio Frustaci. *European Journal of Oncology*, Vol 17 N.2, Oct 2012

- Terapia orale vs terapia infusionale nel trattamento del cancro del colon retto localmente avanzato o avanzato. F.S. Mennini, A. Marcellusi, E. Arduini, G. Mauro, A. Mecozzi, **A. Tuzi**, E. Cortesi. *PharmacoEconomics – Italian Research Articles* 2012; 14 (2): 121-129
- Epirubicin and Docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: results from two successive phase II studies. **Tuzi Alessandro**, Lombardi Davide, Crivellari Diana, Militello Loredana, Perin Tiziana, La Grassa Manuela, Massarut Samuele, Veronesi Andrea. *Accepted-In press by "Radiology and Oncology" 2012*
- Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications. Gianmaria Miolo, Anthony Ash, Angela Buonadonna, Giovanni Lo Re, Elena Torrisi, Silvia Cervo, Davide Adriano Santeufemia, **Alessandro Tuzi**, and Vincenzo Canzonieri. *Cancer Biology & Therapy* 15:11, 1439-1443; Nov 2014
- Mercadante et al. **IOPS MS study group (A. Tuzi)**. Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS). *Adv Ther.* 2017. 34: 120-135
- Biopsy and re-biopsy in the lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration. **Tuzi A**, Bolzacchini E, Suter MB, Giaquinto A, Passaro A, Gobba S, Vallini I, Pinotti G. *J Thorac Dis.* 2017 May;9(Suppl 5):S405-S409.

**On line:**

Updating of genito-urinary cancer of the journal *Ars & Scientia*, available at:

<http://www.informazionisuifarmaci.it/database/fcr/sids.nsf/pagine/E958FBD6FA4359E8C12575A6003211D3?OpenDocument>

**Speaker:**

- Liver tumor board. 01 Apr 2010

Presentation: Case report.

- Diciotto anni dalla prima (Ancona 1992) colectomia laparoscopica. 22 Jun 2010, Roma

Presentation: Trattamento chemioterapico nel carcinoma del retto.

- "Aggiornamento e confronto in tema di colon-retto", 16 Nov 2012, Udine

Presentation: "Maintenance therapy, stop&go, rechallenge: a case report"

- "OLTRE: definire insieme una nuova dimensione della terapia", 21 Oct 2013, Varese

Presentation: "Case report"

- "La pratica clinica nella gestione del paziente con tumore del rene", 08-09 Nov 2013, Sarnico (BG)

Presentation: "Case report"

- "I carcinomi indifferenziati del distretto cervico-facciale" 02 Dec 2013, Varese (VA)

Presentation: "Il trattamento chemioterapico dei tumori indifferenziati della tiroide"

- "Le cure palliative in Hospice" 01 Feb 2014, Hospice ai Pini, Besano (VA)

Presentation: "La gestione dei sintomi gastrointestinali nel paziente oncologico terminale"

- "L'evoluzione terapeutica nel carcinoma prostatico e nel carcinoma renale" 28 Feb 2014, Legnano (VA)

Presentation: "Case report"

- "Le cure palliative in Hospice" 01 Mar 2014, Hospice ai Pini, Besano (VA)  
Presentation: "La gestione dei sintomi respiratori e neuropsichiatrici nel paziente oncologico terminale"
- "Noduli polmonari e diagnosi precoce del tumore del polmone" 04 Apr 2014, Varese (VA)  
Presentation: "Il nodulo polmonare nel follow-up oncologico"
- "Preceptorship sul melanoma" 16-17-18 Apr 2014, Napoli (NA)  
Presentation: "Case report"
- "Le terapie di supporto nella gestione dei trattamenti chemioradioterapici concomitanti per le neoplasie del testa-collo" 29 Oct 2014, Varese (VA)  
Presentation: "Gestione del dolore"
- "Novità e criticità in oncologia nel 2014" 28-29 Nov 2014, Milano (MI)  
Presentation: "Quando la scelta diventa difficile: prima linea ed oltre nel carcinoma renale metastatico"
- "Targeting lung cancer" 30 Mar 2015, Varese (VA)  
Presentation: "Trattamento multimodale del carcinoma polmonare in stadio avanzato"
- "Realtà a confronto nello NSCLC: dalle evidenze alla pratica clinica" 02 Oct 2015, Varese (VA)  
Presentation: "Il paziente EGFR mutato: strategia e gestione"
- "Young in renal", 27 Oct 2015 Baveno  
Presentation: "mRCC: unfit patient"
- Percorso diagnostico-terapeutico del cancro del polmone. 14 Apr 2016, Varese  
Presentation: "Il ruolo dell'oncologo".
- Lung cancer: EBUS-TBNA for diagnosis and staging. 28 Oct 2016, Varese (VA)  
Presentation: Target therapy and immunotherapy based on EBUS biopsy.
- Lung cancer: EBUS-TBNA for diagnosis and staging. 28 Oct 2016, Varese (VA)  
Presentation: Lecture. Role of EBUS-TBNA for lung cancer diagnosis and staging.
- Nuove evidenze nelle terapie della patologia toraco-polmonare. 04 Nov 2016, Biella (BI)  
Presentation: adenocarcinoma polmonare EGFR mutato.
- Gruppo multidisciplinare di oncologia toracica. 17 May 2017, Varese (VA)  
Presentation: ruolo di PDL1 ed EGFR/ALK nelle neoplasie polmonari.

*I consent to the use of my personal data in accordance with the current law (D.L. 196/2003)*

Varese, 10/10/2017

Dr Alessandro Tuzi